Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 15/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23329143 | 0.85 | CD38 (0.72) | CD38SMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL23329133 | 0.84 | CD38 (1.00) | CD38 | |
| SCHEMBL23304751 | 0.82 | CD38 (0.85) | CD38ALDH1A1 | |
| SCHEMBL23329185 | 0.80 | CD38 (0.86) | CD38 | |
| SCHEMBL23329326 | 0.78 | CD38 (0.86) | CD38 | |
| SCHEMBL22932654 | 0.78 | CD38 (0.71) | CD38SMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL22936248 | 0.78 | CD38 (0.71) | CD38 | |
| SCHEMBL23329201 | 0.77 | GAA (0.65) | ADORA2ASMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL22933528 | 0.74 | CD38 (0.72) | CD38 | |
| SCHEMBL23329457 | 0.74 | CD38 (0.46) | CD38SMN1; SMN2KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021087087-A1 | N-CYCLOHEXYL-5-(THIAZOL-5-YL)-1H-INDOLE-7-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS CD38 INHIBITORS FOR INCREASING NAD+ AND FOR THE TREATMENT OF E.G. MUSCULAR DISORDERS | MITOBRIDGE INC. (US) | 2021-05-06 | — | — | WO | disclosed |